3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
1273
Specimen Handling
871
Carboplatin
832
Magnetic Resonance Spectroscopy
808
Cyclophosphamide
803
Cisplatin
729
Nivolumab
659
Paclitaxel
631
Radiotherapy
574
Gemcitabine
572
Biopsy
529
Bevacizumab
476
Dexamethasone
440
fludarabine
407
Docetaxel
378
venetoclax
370
Oxaliplatin
365
Capecitabine
358
Fluorouracil
355
atezolizumab
344
durvalumab
334
Rituximab
333
Doxorubicin
317
Radiosurgery
309
Pemetrexed
306
Drug Therapy
303
Ipilimumab
294
Standard of Care
293
Etoposide
285
Radiation
281
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
gadoterate meglumine
×
1 year
×
Clear all
NCT06057168
2026-01-29
GDX-44-016
Guerbet
Phase 3
Completed
138 enrolled
7 charts
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled